Lew, Thomas E. http://orcid.org/0000-0001-6804-2432
Cliff, Edward R. S. http://orcid.org/0000-0001-5977-907X
Dickinson, Michael
Tam, Constantine S.
Seymour, John F. http://orcid.org/0000-0003-2188-6835
Blombery, Piers
Bajel, Ashish
Ritchie, David
Khot, Amit
Article History
Received: 7 April 2021
Revised: 3 July 2021
Accepted: 7 July 2021
First Online: 20 July 2021
Competing interests
: TEL is an employee of the Walter and Eliza Hall Institute of Medical Research, which receives milestone and royalty payments related to venetoclax. TEL is a recipient of a share in royalty payments paid to the Walter and Eliza Hall Institute of Medical Research. TEL has received honoraria from AbbVie. CST has received honoraria and research funding from AbbVie and Janssen and honoraria from BeiGene. JFS receives research funding from AbbVie, Genentech, Celgene, and Janssen and is an advisory board member for and has received honoraria from AbbVie, Acerta, Celgene, Genentech, Janssen, Roche, Sunesis, and Takeda. AK has received honoraria from Janssen, Celgene, Kyowa, Kirin, and Amgen. AB has received honoraria from Novartis, Amgen, Astellas, Abbvie and speaker fees from Amgen. The remaining authors declare no competing financial interests.